Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 10/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.35 | |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17490581 | 1.00 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL23498013 | 1.00 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL25976125 | 0.99 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL19731615 | 0.95 | FURIN (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL22691442 | 0.95 | FURIN (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL29649550 | 0.94 | PDF (0.38) | FURINSSTR3PDFFOLH1 | |
| SCHEMBL15223879 | 0.93 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL18792771 | 0.93 | HTR2A (0.39) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL17312903 | 0.92 | HTR2A (0.40) | HTR2AFURINMAP1LC3BSSTR3PDF | |
| SCHEMBL26015668 | 0.92 | HTR2A (0.40) | HTR2AFURINMAP1LC3BSSTR3PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
| WO-2021116446-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | HTR2A 1451/4885FURIN 1532/4885MAP1LC3B 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.